Designs and develops implantable lenses for the eye. Manufactures and markets the Visian Implantable Collamer Lens (ICL) family. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
Clearly below the class average.
Growth: Sales growth trails the sector average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
An investor who bought at the very peak is down 82% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $239.4M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 69 buys and 13 sells. Management buying with its own money is usually read as a good sign.
A loss of $80.4M against $239.4M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts about 2.3 years. After that, the company needs to find new money.
On our five-subject report card, STAA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: STAA is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (56/100) says the stock isn’t cheap.